Stifel Maintains Buy on Insmed, Raises Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Stephen Willey maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $67 to $74.
June 05, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Stephen Willey maintains a Buy rating on Insmed and raises the price target from $67 to $74.
The Buy rating and increased price target from a reputable analyst at Stifel is likely to positively influence investor sentiment and drive short-term price appreciation for Insmed.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100